Virax Biolabs Group Ltd. Class A VRAX 深 沪
已收盘 02-06 16:00:00 美东时间
0.2266
+0.005
+2.03%
华盛通- 最 高0.2455
- 今 开0.23
- 成交量 18.54万股
- 最 低 0.22
- 昨 收 0.2221
- 总市值 168.21万
- 52周最高 1.95
- 市盈率 静 --
- 换手率 2.50%
- 52周最低 0.22
- 委 比 33.33%
- 总股本 742.34万
- 历史最高 290.00
- 量 比 1.30
- 振 幅 11.48%
- 历史最低 0.22
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 14.1% to...
01-09 05:06
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Imunon (NASDAQ:IMNN) shares increased by 8.8% to $3.6 during Wednesday...
2025-12-25 05:05
Virax Biolabs Announces $5M Ordinary Shares Offering
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into
2025-12-04 02:58
快讯 | Virax Biolabs Group Limited宣布完成500万美元的私募配售。
Virax Biolabs Group Limited Announces $5 Million Private Placement
2025-12-04 02:53
Virax Biolabs Group Shares Clinical Progress, Intends To Report Clinical Data From UK PAIS Trial In 2026
Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, today highlighted key milestones,
2025-12-03 20:38
Virax Biolabs Completes Patient Recruitment For UK-Based, Multi-Centre Clinical Study Evaluating Performance Of ViraxImmune Assay In Detecting T Cell Dysfunction In PAIS, Including Long COVID, PTLD, And ME/CFS
Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today announced that it has
2025-11-03 21:32
EXCLUSIVE: Virax Biolabs Inks Research Pact To Advance Long COVID Diagnostic Studies
Virax Biolabs partners with Emory University to study its T cell diagnostic ViraxImmune for long COVID, aiming for FDA guidance and U.S. market entry.
2025-08-26 19:15
FibroBiologics announces CFO appointment
FibroBiologics (NASDAQ:FBLG) announced the appointment of Jason D. Davis, CPA, as chief financial officer, effective immediately. Davis most recently served as CFO of Virax Biolabs (VRAX). FBLG shar...
2025-06-09 20:42
美股大行评级 | 潜在涨幅778.38%！HC Wainwright & Co.上调BioLine Rx目标价至26美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1113752959213998081.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持BioLine Rx(BLRX)"买入"评级，目标价从9美元升至26美元</p> <p>• 德银：上调固特异轮胎橡胶(GT)评级至"买入"，目标价13美元</p> <p
2025-04-01 09:48
